In the claims:

1. (**withdrawn**) A method of inhibiting an autoimmune response in a subject comprising administering to said subject an effective amount of an IGF-2 peptide such that said autoimmune response is inhibited.

2. (**withdrawn**) A method of inducing a Th2 immune response in a subject comprising administering to said subject an effective amount of an IGF-2 peptide such that said immune response is induced.

3. (**withdrawn**) A method of inducing tolerance in a subject at risk for developing type I diabetes comprising administering to said subject an effective amount of an IGF-2 peptide such that said tolerance is induced in said subject.

4. (**withdrawn**) A method of restoring tolerance in a subject suffering from type I diabetes comprising administering to said subject an effective amount of an IGF-2 peptide such that said tolerance is restored in said subject.

5. (**withdrawn**) A method for preventing type I diabetes in a subject comprising administering to said subject an effective amount of an IGF-2 peptide, such that said type I diabetes disease is prevented in said subject.

6. (**withdrawn**) A method for treating type I diabetes in a subject comprising administering to said subject an effective amount of an IGF-2 peptide, such that said type I diabetes is treated in said subject

7. (**withdrawn**) A method of protecting a subject at high risk for developing type I diabetes comprising administering an IGF-2 peptide in an amount effective to protect said subject against said type I diabetes.

8. (**withdrawn**) A method of treating graft rejection in a subject receiving grafted islet ß cells comprising administering to said subject an IGF-2 peptide such that said graft rejection is treated.

9. (**withdrawn**) A method of preventing graft rejection in a subject receiving grafted islet ß cells comprising administering to said subject an IGF-2 peptide such that said graft rejection is prevented.

10. **(withdrawn)** The method as in one of claims 1-9, wherein said IGF-2 peptide comprises the amino sequence GELVDTLQFVCGDRG (SEQ ID NO:2; B11-25).

11. **(original)** A vaccine composition for protecting a subject at risk for type I diabetes comprising an IGF-2 peptide and a pharmaceutically acceptable carrier therefor, wherein said IGF-2 peptide is in an amount effective to prevent said type I diabetes in said subject.

12. **(original)** A vaccine composition for inducing tolerance in a subject at risk for developing type I diabetes comprising an IGF-2 peptide and a pharmaceutically acceptable carrier, wherein said IGF-2 peptide is in an amount effective to induce tolerance in said subject.

13. **(original)** The composition as in one of claims 11-12, wherein said IGF-2 peptide comprises the amino sequence GELVDTLQFVCGDRG (SEQ ID NO:2; B11-25).

14. **(canceled)**

15. **(canceled)**

16. **(new)** The composition of one of claims 11-13, wherein said IGF-2 peptide comprises at least 50 amino acids.

17. **(new)** The composition of one of claims 11-13, wherein said IGF-2 peptide comprises at least 75 amino acids.

18. **(new)** The composition of one of claims 11-13, wherein said IGF-2 peptide comprises at least 100 amino acids.

19. **(new)** The composition of one of claims 11-13, wherein said IGF-2 peptide is PEGylated.